Business
US PATIENTS COMMENCE DOSING IN PHASE III STUDY
US PATIENTS COMMENCE DOSING IN PHASE III STUDY.
About this update from Immupharma Plc
[{"type":"text","content":"\n \nRNS Number : 0032P Immupharma PLC 15 February 2016 \n\n\n\n\n\nRNS : FOR IMMEDIATE RELEASE\n\n\n15 FEBRUARY 2016\n\n\n\n\n \n \nFIRST US PATIENTS COMMENCE DOSING IN LUPUZOR'S PIVOTAL PHASE III STUDY\n \n \nImmuPharma PLC (LSE:IMM), (\"ImmuPharma\" or the \"Company\"), the specialist drug discovery and development company, is pleased to provide a further update on the progress of its Phase III clinical trial of Lupuzor™, its lead programme for the potential breakthrough compound for Lupus, the life threatening auto immune disease.\n \nImmuPharma is pleased to confirm that the first US sites opened in December 2015 have now commenced dosing patients. Recruitment in this pivotal Phase III study for Lupuzor™ will occur in up to 45 investigator sites. 10 sites in United States and 35 in Europe.\n \nFurther updates on the progression of the Lupuzor™ Phase III trial will be announced, as appropriate, as the trial progresses. Progress on the trial can also be seen at: www.ClincialTrials.gov/lupuzor.\n \nCommenting on the event, Tim McCarthy, Chairman, said: \"This is the next key milestone for ImmuPharma's Lupuzor™ trial and we are therefore delighted that following the initial US sites being opened, we can now confirm that the first Lupus patients have commenced dosing. With recruitment going to plan, we look forward to providing further positive updates on this Lupuzor™ Phase III study as it progresses throughout this year and 2017.\"\n \n-Ends-\n\n\n\n\nFor further information please contact:\n \n\n\n\n\nImmuPharma plc (www.immupharma.org)\n\n\n+ 44 (0) 20 7152 4080\n\n\n\n\nTim McCarthy, Chairman\n\n\n\n\n\n\n\nLisa Baderoon, Head of Investor Relations\nTwitter: @immupharma\n \n\n\n + 44 (0) 7721 413496\n \n \n\n\n\n\n \nPanmure, Gordon & Co., NOMAD & Broker\n\n\n \n+44 (0) 20 7886 2500\n\n\n\n\nFred Walsh, Duncan Monteith, Corporate Finance\nCharles Leigh-Pemberton, Corporate Broking\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nNotes to Editors\n \nImmuPharma PLC \n \nImmuPharma is a pharmaceutical development company listed since 2006 on AIM of the London Stock Exchange (LSE:IMM), focusing on developing novel medicines with high sales potential in specialist markets with serious unmet need...